re: Ann: MESOBLAST PROVIDES UPDATE ON CLINICA... Ladenburg Thalmann's view on the Prochymal update.
Kevin DeGeeter, Ladenburg Thalmann (4/29/14) "Mesoblast Ltd. expects to meet with the U.S. Food and Drug Administration (FDA) 'shortly' to discuss plans to submit a biologic license application based on existing clinical data, including data from an expanded access program. . .in our view, an update on the program is likely in June 2014 following distribution of written minutes from the FDA meeting. . .we reiterate our Buy rating with a $52 price target."
http://www.thelifesciencesreport.com/pub/co/4251
Note:the current (MBLTY) -Other OTC SP is US$22.30
+13 job applications and 2 recent major league appointments (in Pharma industry).
Please DYOR and Good luck to all.
Ann: MESOBLAST PROVIDES UPDATE ON CLINICAL PROGRA, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.060(5.63%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | $1.00 | $2.066M | 2.029M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 27599 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 15945 | 9 |
View Market Depth
| Last trade - 12.18pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |